OWINGS MILL, MD- Nora Therapeutics Inc., which is developing therapeutics to address issues in womens’ reproductive health, has raised $14.8 million of a targeted $32.55 million round, the company disclosed in a filing with the US Securities and Exchange Commission.

We reported in June that Nora had closed on about $3 million of the round, then aimed at $25 million, according to an SEC filing.

Investors so far include Burrill Life Sciences Capital Fund of San Francisco; Prospect Venture Partners III of Palo Alto, CA; Vivo Ventures Fund VI, Palo Alto.

Nora Therapeutics raised $25 million from Burrill, Prospect Venture Partners and Vivo Ventures in 2008.

Nora is developing products to help women who experience repeated assisted reproduction failure or recurrent miscarriage. It was housed at the Emerging Technology Center in Baltimore in 2004.

We mentioned previously that we like seeing West Coast VCs putting some money into East Coast firms.

We have also been impressed with biotech fund raising in Maryland in general this year. The state has driven development with a number of moves supporting the industry, from programs to provide some early stage funding to establishing a biotechnology center.

Maryland and North Carolina have now and then exchanged places among the top five US biotechnology hubs in annual rankings. Its proximity to the governments National Institutes of Health and the Potomac and Mid-Atlantic venture capital community are distinct advantages.

–Allan Maurer

To reach TJS editor Allan Maurer: Allan at TechJournalSouth dot com.

Join hundreds of Marketing Professionals and Internet Execs at Atlanta’s premier Digital event – Digital Summit 2012
www.digitalsummit.com

Related Stories:

• Nora Therapeutics seeks $25M financing
• Siemens forming $200M VC fund of funds
• Intradigm receives Series A funding and moves HQ to Palo Alto
• Atlanta’s H.I.G. BioVentures raising second $250M fund
• Baltimore-based Pathsensors seeking $2.75M in equity

© 2010, TechJournal. All rights reserved.

Tags: Burrill Life Sciences Capital Fund, CA, DC, financing, MD, NC, Nora Therapeutics, Owings Mills, Palo Alto, Potomac, Prospect Venture Partners III, San Francisco, Vivo Ventures Fund VI, women's reproductive health